Imaging Study of [89Zr]DFO-YS5 for Cancer Detection

StatusRecruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 6 more changesShow less
    • Interventions modified
    • Start date changed from estimate of Aug 1, 2026 to Jun 15, 2026
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study description revised
    • Site details revised
    • Eligibility criteria shortened, about 4 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This is a single-center, pilot, PET-imaging study of the novel radiotracer 89Zirconium-89 DFO conjugated to the YS5 monoclonal antibody (\[89Zr\]DFO-YS5) in participants with nerve sheath tumor, bladder cancer, or advanced solid tumor neoplasms.
Trial Details
NCT Number NCT07664397
Lead Sponsor Robert Flavell, MD, PhD
Collaborators: Kyntra Bio, Fortis Therapeutics, Inc.
Conditions
(from sponsor)		 Bladder Cancer, Nerve Sheath Tumor, Nerve Sheath Tumors, Solid Tumor Malignancies, Solid Tumor Cancer, Solid Tumor Neoplasms, Advanced Solid Tumor, Bladder Neoplasm +4 more
Related terms Nerve Sheath Neoplasms, Pyloric Stenosis, Hypertrophic, Urinary Bladder Neoplasms
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov